News Focus
News Focus
icon url

NASDAQ2020

08/17/13 10:29 PM

#65355 RE: dr_lowenstein #65347

That's what happens when a stock trades on R&D and not financials. ART trials starting this year, patent protected. Innovative superior technology , rock solid , billion dollar revenues expected. ART has been put on priority pps will follow now back to dollar land. $$$$$$$$$$$
icon url

NASDAQ2020

08/17/13 10:51 PM

#65360 RE: dr_lowenstein #65347

Thanks for pointing out the R&D pps for ART opiods. Those suckers should have waited till now to get in. $22/ share is reasonable when ART opiods are launched and required by the FDA and Congress. Competitors are far and few. $22/ share did not include the 20 FDA approved products and did not include Elites 9.99% ownership in one of the largest generic co.s in the USofA, NOVELL LABS.
icon url

Drugdoctor

08/17/13 10:51 PM

#65361 RE: dr_lowenstein #65347

And now it's .085... Thank you again for sharing such important info... A $22 stock for .085... Can you say undervalued????
icon url

Jimmy Joe

08/17/13 11:16 PM

#65369 RE: dr_lowenstein #65347

Yes $22/share. Saint Jerry remembers those $22/share days too.
I agree it will be hysterically funny. I will be laughing all the way to the bank. LOL LOL $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$